title: Interleukin-1-beta and dyslipidemic syndrome as major risk factors for thrombotic complications in type 2 diabetes mellitus.
abstract: Diabetes mellitus (DM) is a complex disease characterized by chronic hyperglycemia, a known risk factor for accelerated atherosclerosis and vascular disease. The aim of this study was to show that the connection between DM and other risk factors, such as dyslipidemia, inflammatory phenomena, or the development of certain vascular injuries, leads to a high frequency of thrombotic events in diabetic patients compared to the nondiabetic population. The study included one hundred eighty patients divided in the following groups: diabetic without ischemic cardiopathy-related disorders (DM), diabetic with clinical or off-clinical (electrocardiogram, cardiac ultrasound) ischemic cardiopathy-related disorders (DM + IC), and nondiabetic with ischemic cardiopathy-related disorders (IC). We investigated the following parameters: von Willebrand Factor, HDL-cholesterol, LDL-cholesterol, interleukin-1-beta, protein C, and plasminogen activator inhibitor type 1. The results achieved in our study have revealed the highest thrombotic risk among the groups of diabetic patients, which is in direct correlation with the high values of interleukin-1-beta and the modifications of lipid parameters, acknowledging the data in the literature, according to which hyperglycemia alters endothelial functions directly and indirectly by synthesis of growth factors and cytokines and generates metabolic disorders which would explain the high risk for thrombotic events.
authors: Department of Pathophysiology, University of Medicine and Pharmacy Grigore T. Popa, Universităţii Street, No. 16, 700115 Iaşi, Romania.
authors: Oana
authors: O
authors: Bădulescu
authors: Codruţa
authors: C
authors: Bădescu
authors: Manuela
authors: M
authors: Ciocoiu
authors: Magda
authors: M
authors: Bădescu
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D008076:Cholesterol, HDL / Q000097:blood; D008078:Cholesterol, LDL / Q000097:blood; D003924:Diabetes Mellitus, Type 2 / Q000097:blood* / Q000150:complications*; D050171:Dyslipidemias / Q000097:blood* / Q000150:complications*; D005260:Female; D006801:Humans; D053583:Interleukin-1beta / Q000097:blood; D008297:Male; D008875:Middle Aged; D017395:Plasminogen Activator Inhibitor 1 / Q000097:blood; D011486:Protein C / Q000378:metabolism; D012307:Risk Factors; D013927:Thrombosis / Q000097:blood* / Q000209:etiology*; D014841:von Willebrand Factor / Q000378:metabolism
chemical_list: D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D053583:Interleukin-1beta; D017395:Plasminogen Activator Inhibitor 1; D011486:Protein C; D014841:von Willebrand Factor
references: Atherosclerosis. 1994 Mar;106(1):83-97
references: 8018110
references: Diabetes Care. 1999 Apr;22 Suppl 3:C25-30
references: 10189559
references: Diabetologia. 1990 Mar;33(3):163-7
references: 2184068
references: J Diabetes Complications. 2002 Nov-Dec;16(6):401-15
references: 12477625
references: Thromb Res. 1983 Jun 1;30(5):487-97
references: 6412388
references: Am J Hypertens. 2001 May;14(5 Pt 1):475-86
references: 11368471
references: Diabetes Care. 2003 Jul;26(7):2181-8
references: 12832332
references: Arterioscler Thromb Vasc Biol. 1998 Sep;18(9):1359-62
references: 9743222
references: Nature. 2000 Apr 13;404(6779):787-90
references: 10783895
references: Diabetes Care. 2001 Aug;24(8):1476-85
references: 11473089
references: Diabetologia. 2003 Jun;46(6):733-49
references: 12774165
references: Am J Cardiol. 2003 Aug 18;92(4A):18J-26J
references: 12957323
references: Diabetologia. 1997 Apr;40(4):454-62
references: 9112023
references: J Clin Invest. 2000 Aug;106(4):453-8
references: 10953019
references: Diabetes. 1982 Nov;31(11):1006-9
references: 6816642
references: JAMA. 2001 Jul 18;286(3):327-34
references: 11466099
references: Nature. 2001 Jan 18;409(6818):307-12
references: 11201732